Xencor appoints Mark Lotz as VP of regulatory affairs and Wayne Saville as VP clinical oncology

13 May 2015

Antibody specialist Xencor (Nasdaq: XNCR) has appointed Mark Lotz as vice president of regulatory affairs and Wayne Saville as vice president of clinical oncology.

Mr Lotz has more than 35 years of experience in biotech and pharma regulatory affairs. Prior to his appointment at Xencor, he served as a regulatory and quality consultant, where he provided review of regulatory documents, clinical development plans and protocols, and served as a representative to regulatory agencies.

Dr Saville has more than 25 years of experience in clinical affairs and medical research and joins the company from Tocagen, where he was vice president of clinical development in oncology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK